Earnings results for Pacira BioSciences (NASDAQ:PCRX)
Pacira BioSciences, Inc. is expected* to report earnings on 05/04/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.37. The reported EPS for the same quarter last year was $0.33.
Pacira BioSciences last released its earnings data on February 24th, 2021. The reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.06. The firm earned $130.90 million during the quarter, compared to analyst estimates of $130.91 million. Its revenue was up 6.9% compared to the same quarter last year. Pacira BioSciences has generated $0.86 earnings per share over the last year and currently has a price-to-earnings ratio of 22.2. Pacira BioSciences has confirmed that its next quarterly earnings report will be published on Tuesday, May 4th, 2021. Pacira BioSciences will be holding an earnings conference call on Tuesday, May 4th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Pacira BioSciences (NASDAQ:PCRX)
12 Wall Street analysts have issued ratings and price targets for Pacira BioSciences in the last 12 months. Their average twelve-month price target is $77.50, predicting that the stock has a possible upside of 22.67%. The high price target for PCRX is $94.00 and the low price target for PCRX is $48.00. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Pacira BioSciences has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $77.50, Pacira BioSciences has a forecasted upside of 22.7% from its current price of $63.18. Pacira BioSciences has only been the subject of 4 research reports in the past 90 days.
Dividend Strength: Pacira BioSciences (NASDAQ:PCRX)
Pacira BioSciences does not currently pay a dividend. Pacira BioSciences does not have a long track record of dividend growth.
Insiders buying/selling: Pacira BioSciences (NASDAQ:PCRX)
In the past three months, Pacira BioSciences insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,470,929.00 in company stock. Only 5.80% of the stock of Pacira BioSciences is held by insiders.
Earnings and Valuation of Pacira BioSciences (NASDAQ:PCRX
Earnings for Pacira BioSciences are expected to grow by 123.26% in the coming year, from $1.29 to $2.88 per share. The P/E ratio of Pacira BioSciences is 22.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.07. The P/E ratio of Pacira BioSciences is 22.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.52. Pacira BioSciences has a PEG Ratio of 0.82. PEG Ratios below 1 indicate that a company could be undervalued. Pacira BioSciences has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here